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Abstract
Objectives. To describe the prevalence of haematological abnormalities in individuals with RA at the point of diagnosis
in primary care and the associations between haematological abnormalities, vaccinations and subsequent risk of
common infections.
Methods. We studied 6591 individuals with newly diagnosed RA between 2004 and 2016 inclusive using the UK Royal
College of General Practitioners Research and Surveillance Centre primary care database. The prevalence of haemato-
logical abnormalities at diagnosis (anaemia, neutropenia and lymphopenia) was established. Cox proportional hazards
models were used to evaluate the association between each haematological abnormality and time to common infections
and the influence of vaccination status (influenza and pneumococcal vaccine) on time to common infections in individuals
with RA compared with a matched cohort of individuals without RA.
Results. Anaemia was common at RA diagnosis (16.1% of individuals), with neutropenia (0.6%) and lymphopenia
(1.4%) less so. Lymphopenia and anaemia were associated with increased infection risk [hazard ratio (HR) 1.18 (95%
CI 1.08, 1.29) and HR 1.37 (95% CI 1.08, 1.73), respectively]. There was no evidence of an association between neu-
tropenia and infection risk [HR 0.94 (95% CI 0.60, 1.47)]. Pneumonia was much more common in individuals with early RA
compared with controls. Influenza vaccination was associated with reduced risk of influenza-like illness only for individ-
uals with RA [HR 0.58 (95% CI 0.37, 0.90)].
Conclusion. At diagnosis, anaemia and lymphopenia, but not neutropenia, increase the risk of common infections in
individuals with RA. Our data support the effectiveness of the influenza vaccination in individuals with RA.
Key words: anaemia, infection, influenza, influenza vaccine, lymphopenia, neutropenia, pneumococcal vaccine,
rheumatoid arthritis
Rheumatology key messages
. Anaemia and lymphopenia are associated with increased infection risk in individuals with early rheumatoid
arthritis.
. Pneumonia is more common in patients with rheumatoid arthritis compared with those without rheumatoid
arthritis.
. Influenza vaccination is associated with a reduced risk of influenza-like illness in patients with rheumatoid arthritis.
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Introduction
The long-term prognosis of RA has improved with the
availability of conventional synthetic and later biologic
DMARDs [1, 2], coupled with greater monitoring and treat-
ment adjustment to target disease remission. EULAR rec-
ommendations suggest the primary target for treatment of
RA should be a state of clinical remission, with low dis-
ease activity an acceptable therapeutic goal, particularly
in patients with a long duration of disease [1].
Haematological abnormalities (including anaemia, neu-
tropenia, and lymphopenia) in RA are common. More than
50% of patients with RA have anaemia [3] and the rela-
tionship between anaemia and disease activity is com-
plex; it is logical to assume that the prevalence of
anaemia should decline with improved disease control
as the underlying cause is often anaemia of chronic dis-
ease [4, 5]. Despite this, iron deficiency anaemia and
macrocytic anaemia have also been reported [69] and
may relate to gastrointestinal blood loss, the presence
of other autoimmune diseases and iatrogenic causes.
DMARD treatment in RA patients has been observed to
influence both lymphocyte and neutrophil counts.
Furthermore, studies have suggested an increased risk
of serious infections with some RA medications, including
with anti-TNF therapies [1013]. Other studies have sug-
gested little or no detectable increase in infectious mor-
bidity or mortality in RA patients with lymphopenia [14,
15]. The effect of lymphocyte and neutrophil counts in
early RA on subsequent infection is not well studied and
could influence treatment choices.
Due to the increased risk of infection, EULAR guidelines
recommend an annual influenza vaccination and a one-off
pneumococcal pneumonia vaccination for individuals with
RA being treated with immunosuppressive medication [16].
UK guidelines recommend the same strategy for other im-
munosuppressed individuals [17, 18]. Despite this, vaccin-
ation uptake has been shown to be suboptimal for
individuals with RA [19, 20], with up to two-thirds of
individuals not receiving the influenza vaccine annually
post-diagnosis [19]; uptake is especially low in younger
age groups [20]. Real-world evidence on the effectiveness
of vaccinations on subsequent infection in individuals with
RA is lacking.
We aimed to establish the association between haem-
atological abnormalities at disease onset and the risk of
common infections in a contemporary RA population. We
also set out to determine associations between vaccin-
ations for influenza and pneumococcal pneumonia and
the subsequent incidence of influenza and pneumococ-
cal-like infections, respectively.
Methods
Data sources and cohort
The Royal College of General Practitioners Research and
Surveillance Centre (RCGP RSC) database comprises the
pseudonymised primary care records of all individuals
registered with a network of general practitioner (GP)
practices distributed across England and provides a
broadly representative sample of the English primary
care population [21]. At the time of data extraction for
this study, data were available from 164 GP practices
with a total population of 1 475 762 people. The RCGP
RSC contains information on clinical diagnoses, anthropo-
metric measurements, laboratory tests and prescriptions
coded with the Read clinical coding systems. The RCGP
is also the primary infectious disease sentinel network for
the UK and has been providing weekly infections data
since 1964. GP practices within the network are provided
with regular feedback on their coding of infectious dis-
eases and therefore the quality of infection recording
within the database is high [21, 22]. Study approval was
granted by the Research Committee of the RCGP RSC.
The study did not require formal ethics board review at a
national level as defined using the National Health Service
(NHS) Health Research Authority research decision tool
(http://www.hra-decisiontools.org.uk/research/).
Infections
Our inclusion criteria specified individuals 518 years of
age with a diagnosis of RA after 1 January 2004 and
prior to 1 January 2017. The study start date was the
date of first RA diagnostic code. RA cases were defined
using established criteria [23]. The follow-up period ex-
tended to the study end: either 1 January 2017, the date
of patient transfer from an included practice, or death.
Vaccinations
We determined the impact of influenza and pneumococcal
vaccinations on, respectively, a recorded diagnosis of an
influenza-like illness and pneumonia in individuals with RA.
A matched cohort analysis was also performed to compare
the relative efficacy of influenza and pneumococcal vaccin-
ation in individuals with RA compared with those without.
For this analysis we included individuals with RA diagnosed
after January 2004 but before 1 January 2012. Cases were
age- and sex-matched one to one with controls without RA
at a GP practice level using nearest-neighbour matching.
For this analysis, the start of follow-up was 1 January 2012.
This approach enabled comparisons of individuals with and
without RA over the same influenza and pneumonia sea-
sons (5 years total follow-up), reducing bias due to differing
strains of infective pathogens and variation in vaccination
programmes.
The influenza vaccination is typically repeated annually,
whereas the pneumococcal vaccination is given only
once. Vaccination status at baseline was therefore defined
for influenza vaccination to be the presence of any code or
prescription for an influenza vaccination in the year before
the start of follow-up (1 January 2012). For pneumococcal
vaccination it was defined as any code or prescription for
a pneumococcal vaccination at any time prior to 1 January
2012.
Definition of haematological abnormalities at baseline, in
the 3 years prior to diagnosis and at 3 years post-
diagnosis
Haematological abnormalities and other baseline meas-
ures were derived by taking the average of up to three
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most recent values in the 12 months prior to diagnosis. We
evaluated time trends in the proportion of individuals with
haematological abnormalities at 1, 2 and 3 years pre-diag-
nosis using the same definition. The proportion of individ-
uals with RA with haematological abnormalities 3 years
post-diagnosis was evaluated in those with sufficient
follow-up.
Code lists used to define haematological abnormalities
were developed in accordance with published recommen-
dations [24, 25]. Anaemia was defined as a mean haemo-
globin <13.5 g/dl (135 g/L) for men or <11.5 g/dl (115 g/L)
for women. Neutropenia was defined as a mean total neu-
trophil count <1.6 109/L and lymphopenia was defined
as a mean total lymphocyte count <0.75 109/L. Further
subdivision by severity was not possible due to low num-
bers. Baseline medication use was defined as the issuing
of a prescription 3 months before to 30 days after diagno-
sis. This was to allow a period for the transfer of prescrib-
ing from secondary care to primary care; the initial
prescription is often issued in secondary care with
repeat prescriptions issued from primary care.
Outcomes
The primary outcome was the time to first recorded pres-
entation with a new episode of infection during the study
period. The primary outcome comprised an a priori com-
posite of upper respiratory tract infections, bronchitis, in-
fluenza-like illness, pneumonia, intestinal infectious
diseases, herpes simplex, skin and soft tissue infections,
urinary tract infections and genital and perineal infections.
The Read codes used to identify infections were taken
from the validated indicators used in routine surveillance
by the RCGP RSC. The chosen infections were selected
principally because they represent the majority of the pri-
mary care adult infectious disease burden, include a mix-
ture of viral, bacterial and fungal infections and affect a
range of different body systems. They also comprise the
key infectious disease monitored as part of the RCGP
RSC network and therefore GPs are provided with regular
feedback on the coding quality of these conditions. First
or new episodes of an infection are coded accordingly in
the database, enabling differentiation from chronic infec-
tions or follow-up visits for the same episode. For the
evaluation of influenza and pneumococcal pneumonia
vaccination, the outcomes were time to first recorded
presentation with an episode of influenza-like illness and
pneumonia over the study period, respectively.
Statistical analyses
Infections
We evaluated differences in baseline characteristics be-
tween those with and without haematological abnormal-
ities; all reported P-values are two-sided. Event rates were
calculated as the number of events divided by the total
person-years of follow-up and expressed as the number
per 1000 person-years.
Baseline analysis. The influence of each baseline haem-
atological abnormality (anaemia, lymphopenia and neutro-
penia) on time to first infection was evaluated using
separate unadjusted Cox proportional hazards models
and a multivariable adjusted Cox model. The multivariable
model was adjusted for age, sex, ethnicity and baseline
measures of BMI, smoking status, medication use, sero-
positivity and comorbidities (detailed in Table 1).
Time-varying analysis. To evaluate the influence of
haematological abnormalities after diagnosis on risk of in-
fection, we updated the same unadjusted and adjusted
Cox models used in the baseline analysis to include
haematological measures across follow-up as time-vary-
ing covariates. Each haematological abnormality was
classified as a time-varying binary exposure: the presence
or absence of an abnormality on the most recent full blood
count test. In this analysis, individuals were able to tran-
sition from one haematological state to another (e.g. neu-
tropenic to non-neutropenic) multiple times during the
follow-up period. Haematological results recorded in the
2 weeks prior to an infection were excluded to reduce the
likelihood the infection itself influenced the haematological
measures.
Vaccinations
We assessed differences in the effectiveness of vaccin-
ations for influenza and pneumococcus among patients
with RA and those without RA by comparing incidences
of these infections in subgroups who had and had not
undergone immunization. Comparisons were made using
the 2 test. Time to infection by vaccination status was
evaluated separately in individuals with and without RA
using unadjusted and adjusted Cox models, with adjust-
ment for age, sex, ethnicity, BMI, smoking status, comor-
bidities likely to influence vaccination status [chronic
obstructive pulmonary disease (COPD), asthma, diabetes,
chronic kidney disease (CKD)], use of immunosuppressive
agents and, in those with RA, the duration of RA and RA
autoantibody status. To test for an overall effect of het-
erogeneity by RA status and vaccination status, we used a
likelihood ratio test to compare a model with an RA status
and vaccination status interaction term with a nested
model without an interaction term. Statistical analyses
were performed in R version 3.4.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
A total of 6591 individuals were diagnosed with RA, the
majority (67%) were female (Table 1). The median follow-
up was 2.2 years. At baseline, anaemia was present in
1066 (16.2%) individuals; neutropenia [n= 38 (0.6%)] and
lymphopenia [n= 97 (1.5%)] were less common. The pro-
portion of individuals with anaemia increased in the years
prior to diagnosis (5.1% of individuals had anaemia 3
years prior to diagnosis, 6.3% 2 years prior and 8.3% 1
year prior). The proportion with neutropenia and lympho-
penia was 0.2-0.4% and 0.4-0.6%, respectively, over the
same pre-diagnosis period (Table 2). At 3 years post-diag-
nosis the proportion of individuals with each haematolo-
gical abnormality remained similar to at diagnosis
(anaemia 15.9%, neutropenia 1.1%, lymphopenia 1.5%;
Table 2).
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Baseline patient characteristics differ by
haematological status
Baseline characteristics of the study population, over-
all and by haematological abnormality, are shown in
Table 1 and Supplementary Table S13, available at
Rheumatology online. Individuals with anaemia and
lymphopenia were older than the study population as a
whole. Individuals with anaemia were more likely to be
male and had greater comorbidity, while individuals with
neutropenia were more likely to be of black ethnicity.
Anaemia and lymphopenia are associated with an
increased risk of infection
Crude rates of infection among individuals with baseline
anaemia, neutropenia and lymphopenia were 181.2, 151.8
and 256.4 per 1000 person-years, respectively, compared
with 172.0 per 1000 person-years among individuals with-
out haematological abnormality. Baseline anaemia and
lymphopenia were associated with an increased risk of
infection in both unadjusted and adjusted analyses
(Table 3). There was no evidence of an association for
TABLE 1 Baseline characteristics at diagnosis for individuals with RA by haematological abnormality
Characteristics
Overall
(n=6591)
Anaemia
(n=1066) P-valuea
Neutropenia
(n=38) P-valueb
Lymphopenia
(n=97) P-valuec
Age, mean (S.D.), years 58.7 (15.5) 63.9 (15.6) <0.001 59.8 (13.2) 0.64 64.0 (15.3) 0.001
Sex, male, n (%) 2142 (32.5) 556 (52.2) <0.001 16 (42.1) 0.27 32 (33.0) 1.00
Ethnicity, n (%) <0.001 <0.001 0.542
White 4883 (74.1) 740 (69.4) 17 (44.7) 74 (76.3)
Asian 255 (3.9) 65 (6.1) 3 (7.9) 2 (2.1)
Black 128 (1.9) 26 (2.4) 11 (28.9) 0 (0.0)
Mixed 26 (0.4) 7 (0.7) 0 (0.0) 0 (0.0)
Other 36 (0.5) 4 (0.5) 0 (0.0) 0 (0.0)
Missing 1263 (19.2) 224 (21) 7 (18.4) 21 (21.6)
Smoking status, n (%) <0.001 0.016 0.196
Never 1853 (28.1) 294 (27.6) 12 (31.6) 32 (33.0)
Current 1348 (20.5) 167 (15.7) 5 (13.2) 15 (15.5)
Former 2968 (45.0) 528 (49.5) 14 (36.8) 40 (41.2)
Missing 422 (6.4) 77 (7.2) 7 (18.4) 10 (10.3)
BMI, mean (S.D.), kg/m2d 27.7 (6.0) 27.2 (6.3) 0.010 26.7 (4.8) 0.349 26.1 (6.4) 0.008
Comorbidities, n (%)
Atrial fibrillation 237 (3.6) 61 (5.7) <0.001 1 (2.6) 1.000 5 (5.2) 0.578
Hypertension 2063 (31.3) 441 (41.4) <0.001 15 (39.5) 0.361 33 (34.0) 0.637
Myocardial infarction 202 (3.1) 59 (5.5) <0.001 0 0.530 5 (5.2) 0.365
Stroke 254 (3.9) 82 (7.7) <0.001 3 (7.9) 0.381 5 (5.2) 0.686
Heart failure 108 (1.6) 37 (3.5) <0.001 0 0.875 1 (1.0) 0.943
CKD Stages IIIV 618 (9.4) 177 (16.6) <0.001 4 (10.5) 1.000 12 (12.4) 0.399
Diabetes 735 (11.2) 187 (17.5) <0.001 3 (7.9) 0.703 14 (14.4) 0.383
COPD 466 (7.1) 79 (7.4) 0.683 1 (2.6) 0.451 11 (11.3) 0.146
Asthma 1118 (17.0) 179 (16.8) 0.906 4 (10.5) 0.399 14 (14.4) 0.594
Malignancy 369 (5.6) 75 (7.0) 0.031 2 (5.3) 1.000 3 (3.1) 0.390
Metastatic cancer 62 (0.9) 17 (1.6) 0.025 0 1.000 2 (2.1) 0.534
Depression 1855 (28.1) 234 (22.0) <0.001 7 (18.4) 0.248 21 (21.6) 0.187
Haematological/lab values,
mean (S.D.)
Haemoglobin (g/L)d 13.2 (1.5) 11.6 (1.4) <0.001 12.7 (1.8) 0.020 12.2 (1.7) <0.001
Neutrophil count (109/L)d 4.7 (2.6) 5.0 (2.5) <0.001 1.3 (0.4) <0.001 4.5 (2.7) 0.483
Lymphocyte count (109/L)d 2.0 (1.0) 1.7 (0.8) <0.001 1.6 (0.6) 0.008 0.6 (0.2) <0.001
Seropositivee 1791 (27) 269 (25) 0.129 13 (34) 0.427 21 (22) 0.264
Medications, n (%)
NSAIDs 1962 (29.8) 314 (29.5) 0.836 10 (26.3) 0.773 21 (21.6) 0.099
Glucocorticoids 2001 (30.4) 433 (40.6) <0.001 7 (18.4) 0.153 58 (59.8) <0.001
Methotrexate 992 (15.1) 197 (18.5) 0.001 5 (13.2) 0.921 22 (22.7) 0.048
Other csDMARDs 1263 (19.2) 260 (24.4) <0.001 6 (15.8) 0.747 42 (43.3) <0.001
bDMARDs 19 (0.3) 2 (0.2) 0.721 0 (0.0) 1.000 1 (1.0) 0.674
aP-value for differences when compared with those without anaemia.
bP-value for differences when compared with those without neutropenia.
cP-value for differences when compared with those without lymphopenia.
dMissing baseline data: BMI, n= 520 (8%); haemoglobin, n= 499 (8%); neutrophils, n= 530 (8%); lymphocytes, n= 526 (8%).
eBased on RF or anti-CCP antibody (%). bDMARDs, biological DMARDs; csDMARDs, conventional synthetic DMARDs.
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baseline neutropenia. For a breakdown of infection types
see Supplementary Table S4, available at Rheumatology
online.
Incorporating haematological measures throughout
follow-up identified many more individuals with at least
one test indicating haematological abnormality (anaemia
34% of individuals, neutropenia 4%, lymphopenia 9%)
compared with the assessment of baseline haematological
measures. The median number of test measures per indi-
vidual was 6 (interquartile range 218). Consistent with the
analysis of baseline measures, anaemia and lymphopenia
were associated with an increased risk of infection (Table 4).
Vaccination
We identified 3699 individuals with a diagnosis of RA
before 1 January 2012 and all were matched with controls
(Supplementary Table S5, available at Rheumatology
online). During a follow-up of 31 660 person-years, 168
influenza-like illness and 150 pneumonia events were re-
corded. Table 5 shows the infection rates and risk of
infection associated with vaccination status among indi-
viduals with and without RA.
Pneumonia. A higher proportion of individuals with RA
were vaccinated against pneumococcal pneumonia com-
pared with individuals without RA (16% vs 12%,
P< 0.001; Table 5). Event rates for pneumonia in both
the vaccinated and non-vaccinated group (7.7 and 6.9
per 1000-person years, respectively) exceeded those
among individuals without RA (5.9 and 2.1 per 1000-
person years, respectively). Pneumococcal vaccination
was associated with an increased risk of pneumonia in
those without RA, but we found no evidence of an asso-
ciation among individuals with RA (test for RA: vaccination
status interaction in multivariable model P= 0.14).
Influenza. A higher proportion of individuals with RA
were vaccinated against influenza compared with individ-
uals without RA (64% vs 48%, P < 0.001; Table 5). Among
the non-vaccinated, the event rate for influenza-like illness
among individuals with RA was slightly increased com-
pared with individuals without RA (Table 5). Vaccination
was associated with a reduction in influenza-like illness in
those with RA [hazard ratio (HR) 0.59 (95% CI 0.36, 0.98)],
but there was no evidence of an association in those with-
out RA [HR 0.95 (95% CI 0.55, 1.64)] (test for RA: vaccin-
ation status interaction in multivariable model P= 0.24).
Discussion
This study provides the most comprehensive evaluation to
date of the association between haematological abnorm-
alities at disease onset and risk of common infection
among individuals with RA. Anaemia and lymphopenia,
but not neutropenia, at and after diagnosis were asso-
ciated with an increased risk of infection. Our study pro-
vides important real-world evidence that the influenza
vaccine is effective in people with RA. We also found in-
dividuals with RA had higher rates of pneumonia when
compared with matched individuals and provide the first
TABLE 3 Adjusted HRs of infections by the presence or absence of haematological abnormality at baseline
Abnormality
No haematological
abnormality (n=5499)
Anaemia
(n=1066)
Neutropenia
(n=38)
Lymphopenia
(n=97)
Infection events, n (%) 3506 (53.2) 658 (61.7) 19 (50.0) 73 (75.3)
Exposure time, person-years 20 384 3631 125 285
Event rate per 1000 person-years,
median (IQR)
172.0 (166.4177.8) 181.2 (167.7195.6) 151.8 (91.4237.0) 256.4 (201.0322.4)
Unadjusted HR (95% CI) Reference 1.09 (1.00, 1.18) 0.90 (0.54, 1.41) 1.49 (1.18, 1.88)
Adjusted HR (95% CI)a Reference 1.19 (1.08, 1.30) 1.06 (0.67, 1.67) 1.41 (1.11, 1.79)
aAdjusted for age, sex, ethnicity (white/missing or non-white), baseline measures of other haematological measures, BMI
category (<18.5 underweight, 18.524.9 normal weight, 25.029.9 overweight, 30.034.9 class I obesity, 35.039.9 class II
obesity, 540.0 class III obesity, missing), smoking status (never, current, former, missing), seropositivity (presence of RF or
anti-CCP antibodies), medication use and comorbidities (see Table1). IQR, interquartile range.
TABLE 2 The proportion of individuals with RA with recorded haematological abnormalities before, at and after
diagnosis
Abnormality
3 years
pre-diagnosis
(n=5,535)
2 years
pre-diagnosis
(n=5,731)
1 year
pre-diagnosis
(n=5,901)
At diagnosis
RA (n=6,591)
3 years
post-diagnosis
(n=4646)
Anaemia 284 (5.1%) 361 (6.3%) 488 (8.3%) 1066 (16.1%) 739 (15.9%)
Neutropenia 14 (0.2%) 19 (0.3%) 25 (0.4%) 38 (0.6%) 56 (1.1%)
Lymphopenia 25 (0.4%) 25 (0.4%) 38 (0.6%) 97 (1.4%) 75 (1.5%)
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data to suggest the efficacy of the pneumococcal vaccine
may differ in individuals with and without RA.
In this study we used a large primary care database
and considered a broad range of common infections pre-
senting to primary care physicians, meaning we provide
information on more than six times as many individuals
with RA and five times as many infection events as the
only previous population-based study to evaluate the
impact of haematological abnormalities on infection
risks [26]. In the previous study, Crowson et al. [26]
found infection risks were increased by 45% [HR 1.45
(95% CI 0.86, 2.43)] in the presence of lymphopenia
and by 76% [HR 1.76 (95% CI 0.42, 7.37)] with neutro-
penia in a population-based cohort from Minnesota in the
USA. The wide CIs reported and the different settings
and infections considered (Crowson et al. [26] con-
sidered only serious infections requiring hospitalization
or intravenous antibiotics), limit direct comparison of
our results with this previous study.
Although we found no evidence that the presence of
neutropenia was associated with an increase in infections,
few individuals had neutropenia, limiting the power of our
study. Our findings do not imply that neutropenia induced
in some patients receiving DMARDs is benign, given pre-
vious studies [27, 28]. The high prevalence of anaemia in
individuals with RA is in keeping with previous studies
[19], but further studies are required to establish whether
proactive anaemia management may be beneficial in early
RA in the context of infection risk.
Uptake of both influenza and pneumococcus vaccine
prior to diagnosis was greater among individuals with
RA compared with matched controls without RA. In the
case of influenza, after adjustment for a range of patient
characteristics and comorbidities that have previously
been shown to be associated with infection risk [26], an
approach designed to reduce the possibility of confound-
ing by indication [29], we also observed a protective effect
of vaccination in individuals with RA. In individuals without
TABLE 5 HRs of infection outcomes by vaccination status
Outcome
No RA (n=3699) RA (n=3699)
Not vaccinated Vaccinated Not vaccinated Vaccinated
Pneumonia vaccinations, n (%) 3239 (88) 460 (12) 3093 (84) 606 (16)
Pneumonia events, n (%) 30 (1) 12 (3) 88 (3) 20 (3)
Exposure time, person-years 14 401 2032 12 780 2601
Event rate per 1000 person-years, median (IQR) 2.1 (1.43.0) 5.9 (3.110.3) 6.9 (5.58.5) 7.7 (4.711.9)
Unadjusted HR (95% CI) Reference 2.84 (1.45, 5.54) Reference 1.12 (0.69, 1.82)
Adjusted HR (95% CI)a Reference 2.03 (1.00, 4.11) Reference 0.90 (0.55, 1.48)
Influenza vaccinations, n (%) 1920 (52) 1779 (48) 1348 (36) 2351 (64)
Influenza-like illness events, n (%) 57 (3) 34 (2) 35 (3) 42 (2)
Exposure time, person-years 8484 7842 4951 10383
Event rate per 1000 person-years, median (IQR) 6.7 (5.18.7) 4.3 (3.06.1) 7.1 (4.99.8) 4.0 (2.95.5)
Unadjusted HR (95% CI) Reference 0.65 (0.42, 0.99) Reference 0.58 (0.37, 0.90)
Adjusted HR (95% CI)a Reference 0.95 (0.55, 1.64) Reference 0.59 (0.36, 0.98)
aAdjusted for age, sex, ethnicity (white/missing or non-white), BMI category (<18.5 underweight, 18.524.9 normal weight,
25.029.9 overweight, 30.034.9 class I obesity, 35.039.9 class II obesity, 540.0 class III obesity, missing), smoking status
(never, current, former, missing), comorbidities (COPD, asthma, diabetes, CKD), use of immunosuppressive agents and, in
those with RA, the duration of RA and seropositivity (presence of RF or anti-CCP antibodies.
TABLE 4 HRs of infections by time-varying haematological abnormality status across study follow-up
Status Anaemia Neutropenia Lymphopenia
Individuals with at least one episode across follow-up, n 2220 259 562
Unadjusted HR (95% CI) 1.13 (1.04, 1.24) 1.10 (0.74, 1.63) 1.46 (1.17, 1.81)
Adjusted HR (95% CI)a 1.21 (1.10, 1.33) 1.19 (0.80, 1.76) 1.39 (1.12, 1.73)
HRs represent the increase in the risk of infections associated with the presence of each haematological abnormality at any
time during study follow-up compared with the absence of the haematological abnormality in the total study population with
RA (n= 6591; infection events, n= 3506).
aAdjusted for age, sex, ethnicity (white/missing or non-white), baseline measures of other haematological measures, BMI
category (<18.5 underweight, 18.524.9 normal weight, 25.029.9 overweight, 30.034.9 class I obesity, 35.039.9 class II
obesity, 540.0 class III obesity, missing), smoking status (never, current, former, missing), seropositivity (presence of RF or
anti-CCP antibodies), medication use and comorbidities (see Table1).
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RA, there was no evidence that vaccination was asso-
ciated with a reduced risk of influenza.
We found no evidence of a protective effect for the
pneumococcus vaccine in patients with RA. This may
relate to a lack of specificity of the infection outcome, as
primary care coding does not allow for identification of
microbiologically confirmed pneumococcal pneumonia.
As a result clinical codes likely cover both true pneumo-
coccal pneumonia and the majority of pneumonias that
are caused by pneumococcal strains or other pathogens
not covered by the vaccine. The positive association be-
tween pneumococcal vaccination and pneumonia events
we observed in the non-RA cohort may be explained by a
further common bias evaluating vaccine efficacy in routine
data; if patients at higher risk of pneumonia are more likely
to be vaccinated, higher infection rates may be seen
among vaccinated individuals than non-vaccinated indi-
viduals, and an underestimation of vaccine effectiveness
will be made [30]. Such bias may also explain the appar-
ent lack of efficacy of the influenza vaccine in people with-
out RA. Identification and elimination of confounding by
indication is difficult [31], and our results highlight the po-
tential limitations of vaccine efficacy studies using routine
observational data. Despite these limitations, it is should
be noted that in fully adjusted analyses, influenza vaccin-
ation offered a protective effect in individuals with RA but
not in matched patients.
The strengths of the study include the use of primary
care data from a nationally representative sample of the
UK [21]. The RCGP RSC network is the principle infections
surveillance network in the UK and provides regular feed-
back about the quality of infection recording and reporting
to constituent practices. The infection incidence data are
therefore the highest quality available using routine health
care records.
Limitations of the study include the fact that data are
observational and therefore the possibility of residual
confounding as an explanation of our findings cannot
be excluded, despite attempts to reduce it through the
use of a matched cohort design and by adjustment for
likely measured confounders. In particular, there remains
a potential diagnostic bias if individuals with RA are more
likely to visit their general practitioner compared with in-
dividuals without RA, in particular at times of infection or
infection-like symptoms. Despite the use of a matched
design for the vaccination analysis there remained differ-
ences in baseline factors between the RA and non-RA
populations, with individuals with RA having higher levels
of, in particular, smoking, COPD, asthma and CKD.
Although these factors and other relevant clinical vari-
ables, including medication use, were adjusted for in
multivariable analysis, unmeasured differences unrelated
to the presence or absence of RA are a potential explan-
ation of the differences in vaccine efficacy we observed.
In common with other studies using primary care re-
cords, our study relied on the use of comprehensive
code lists, against which all variables were defined.
This limitation was mitigated, however, by the use of a
validated approach for case ascertainment and defining
variables [24, 25]. A further limitation is that our definition
of RA was based on primary rather than specialist care
records, and results may not be applicable to dissimilar
populations.
Future work
Our results demonstrate robust associations between
haematological markers and risk of common infections.
Further study of the clinical utility of these markers in con-
temporary real-world RA populations would be of consid-
erable interest. This could involve interrogation of hospital
admissions data to evaluate associations with more ser-
ious infection events. An evaluation of whether existing
risk scores for infection can be improved through inclu-
sion of haematological abnormality markers and thereby
help guide clinical management would be of particular
interest [32, 33]. Given the apparent effectiveness of influ-
enza vaccination in individuals with RA we demonstrated
in this study, further studies to explore rates of annual flu
vaccine uptake among people with RA and reasons for
remaining unvaccinated would be of interest to encourage
improvement in vaccination rates. Further studies, ideally
evaluating confirmed pneumococcal disease, are required
to determine the efficacy of pneumococcal vaccination in
individuals with RA and examine how efficacy is modified
by RA therapy [34].
Conclusions
Anaemia and lymphopenia in individuals with RA are in-
dependently associated with an increased risk of common
infection. This suggests haematological markers may be
clinically useful to identify individuals who might benefit
from targeted counselling to stress the importance of
early presentation if symptoms of infection develop. Our
data show a higher rate of pneumococcal-like illness in
individuals with RA and support the effectiveness of the
influenza vaccination in people with RA.
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